Table 3 Oncogenic/tumor-suppressive role of ITGB1 in various cancers

Gastric carcinoma (GC)

Oncogenic

Protein expression

The FAK pathway

[36,37,38,39,40]

Oncogenic

Protein expression

The BCL9L/β-catenin/BCL2 signaling pathway

[88]

Hepatocellular carcinoma (HCC)

Oncogenic

Protein expression

FAK/PI3K/AKT pathways

[42, 61, 62]

Oncogenic

Protein expression

[41, 43, 52]

Oncogenic

Protein expression

PXN/YWHAZ/AKT pathways

[108]

Colorectal carcinoma (CRC)

Oncogenic

Protein expression

The FAK/Wnt pathways

[63]

EMT

[44]

[53, 111]

The AKT‐dependent pathway

[49]

The F‐actin/TRIM11/PFK/HIF1α pathways

[90]

Pancreatic ductal adenocarcinoma (PDAC)

Oncogenic

Protein expression

[51, 64, 65, 117]

Breast cancer (BC)

Oncogenic

Protein expression

[54, 56, 57]

FAK/SRC pathways

[55]

Oncogenic

Protein expression

[47]

RING1/Rad51 pathways

[118]

Epithelial ovarian cancer (EOC)

Oncogenic

Protein expression

[60, 66]

Oncogenic

Protein expression

Periostin signaling in CAFs

[48]

Cutaneous squamous cell carcinomas

Oncogenic

Protein expression

[67]

Lung cancer

Oncogenic

Protein expression

[58, 97]

Prostate cancer

Oncogenic

Protein expression

[69, 70]

Oncogenic

Protein expression

TGFβ signaling pathways

[45]

Oncogenic

Increased activation in CAFs

High traction forces produced by CAFs were transduced to Fn pathways

[80]

Glioma

Oncogenic

Protein expression

FAK signaling pathways

[71]

Oral squamous cell carcinoma (OSCC)

Oncogenic

Protein expression

[59]

Melanoma

Oncogenic

Protein expression

[72] [50, 95]

Cholangiocarcinoma (CCA)

Oncogenic

Protein expression

[73]